218 related articles for article (PubMed ID: 19679597)
1. Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis.
MacLeod DL; Barker LM; Sutherland JL; Moss SC; Gurgel JL; Kenney TF; Burns JL; Baker WR
J Antimicrob Chemother; 2009 Oct; 64(4):829-36. PubMed ID: 19679597
[TBL] [Abstract][Full Text] [Related]
2. Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions.
McCaughey G; McKevitt M; Elborn JS; Tunney MM
J Cyst Fibros; 2012 May; 11(3):163-72. PubMed ID: 22138067
[TBL] [Abstract][Full Text] [Related]
3. Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection.
Trapnell BC; McColley SA; Kissner DG; Rolfe MW; Rosen JM; McKevitt M; Moorehead L; Montgomery AB; Geller DE;
Am J Respir Crit Care Med; 2012 Jan; 185(2):171-8. PubMed ID: 22095545
[TBL] [Abstract][Full Text] [Related]
4. Eradication of Pseudomonas aeruginosa biofilms on cultured airway cells by a fosfomycin/tobramycin antibiotic combination.
Anderson GG; Kenney TF; Macleod DL; Henig NR; O'Toole GA
Pathog Dis; 2013 Feb; 67(1):39-45. PubMed ID: 23620118
[TBL] [Abstract][Full Text] [Related]
5. Resistance development of cystic fibrosis respiratory pathogens when exposed to fosfomycin and tobramycin alone and in combination under aerobic and anaerobic conditions.
McCaughey G; Diamond P; Elborn JS; McKevitt M; Tunney MM
PLoS One; 2013; 8(7):e69763. PubMed ID: 23936095
[TBL] [Abstract][Full Text] [Related]
6. Fosfomycin enhances the active transport of tobramycin in Pseudomonas aeruginosa.
MacLeod DL; Velayudhan J; Kenney TF; Therrien JH; Sutherland JL; Barker LM; Baker WR
Antimicrob Agents Chemother; 2012 Mar; 56(3):1529-38. PubMed ID: 22232284
[TBL] [Abstract][Full Text] [Related]
7. Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance.
Walsh CC; Landersdorfer CB; McIntosh MP; Peleg AY; Hirsch EB; Kirkpatrick CM; Bergen PJ
J Antimicrob Chemother; 2016 Aug; 71(8):2218-29. PubMed ID: 27118778
[TBL] [Abstract][Full Text] [Related]
8. Use of Calgary and Microfluidic BioFlux Systems To Test the Activity of Fosfomycin and Tobramycin Alone and in Combination against Cystic Fibrosis Pseudomonas aeruginosa Biofilms.
Díez-Aguilar M; Morosini MI; Köksal E; Oliver A; Ekkelenkamp M; Cantón R
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084746
[No Abstract] [Full Text] [Related]
9. Antibacterial effect of seven days exposure to ceftolozane-tazobactam as monotherapy and in combination with fosfomycin or tobramycin against Pseudomonas aeruginosa with ceftolozane-tazobactam MICs at or above 4 mg/l in an in vitro pharmacokinetic model.
Attwood M; Griffin P; Noel AR; Albur M; Macgowan AP
J Antimicrob Chemother; 2023 Sep; 78(9):2254-2262. PubMed ID: 37527369
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial Activity of Fosfomycin-Tobramycin Combination against Pseudomonas aeruginosa Isolates Assessed by Time-Kill Assays and Mutant Prevention Concentrations.
Díez-Aguilar M; Morosini MI; Tedim AP; Rodríguez I; Aktaş Z; Cantón R
Antimicrob Agents Chemother; 2015 Oct; 59(10):6039-45. PubMed ID: 26195514
[TBL] [Abstract][Full Text] [Related]
11. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis.
Burns JL; Van Dalfsen JM; Shawar RM; Otto KL; Garber RL; Quan JM; Montgomery AB; Albers GM; Ramsey BW; Smith AL
J Infect Dis; 1999 May; 179(5):1190-6. PubMed ID: 10191222
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of antibiotic combinations in an experimental sepsis model with Pseudomonas aeruginosa.
Aktas Z; Sonmez N; Oksuz L; Boral O; Issever H; Oncul O
Braz J Microbiol; 2023 Dec; 54(4):2817-2826. PubMed ID: 37828396
[TBL] [Abstract][Full Text] [Related]
13. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis.
Bilton D; Henig N; Morrissey B; Gotfried M
Chest; 2006 Nov; 130(5):1503-10. PubMed ID: 17099030
[TBL] [Abstract][Full Text] [Related]
14. In-vitro bactericidal efficacy of sub-MIC concentrations of liposome-encapsulated antibiotic against gram-negative and gram-positive bacteria.
Beaulac C; Sachetelli S; Lagace J
J Antimicrob Chemother; 1998 Jan; 41(1):35-41. PubMed ID: 9511035
[TBL] [Abstract][Full Text] [Related]
15. Activity of innate antimicrobial peptides and ivacaftor against clinical cystic fibrosis respiratory pathogens.
Payne JE; Dubois AV; Ingram RJ; Weldon S; Taggart CC; Elborn JS; Tunney MM
Int J Antimicrob Agents; 2017 Sep; 50(3):427-435. PubMed ID: 28666755
[TBL] [Abstract][Full Text] [Related]
16. New perspectives for reassessing fosfomycin: applicability in current clinical practice.
Candel FJ; Matesanz David M; Barberán J
Rev Esp Quimioter; 2019 May; 32 Suppl 1(Suppl 1):1-7. PubMed ID: 31131586
[TBL] [Abstract][Full Text] [Related]
17. Amikacin-fosfomycin at a five-to-two ratio: characterization of mutation rates in microbial strains causing ventilator-associated pneumonia and interactions with commonly used antibiotics.
Montgomery AB; Rhomberg PR; Abuan T; Walters KA; Flamm RK
Antimicrob Agents Chemother; 2014 Jul; 58(7):3708-13. PubMed ID: 24752276
[TBL] [Abstract][Full Text] [Related]
18. Fosfomycin and tobramycin in combination downregulate nitrate reductase genes narG and narH, resulting in increased activity against Pseudomonas aeruginosa under anaerobic conditions.
McCaughey G; Gilpin DF; Schneiders T; Hoffman LR; McKevitt M; Elborn JS; Tunney MM
Antimicrob Agents Chemother; 2013 Nov; 57(11):5406-14. PubMed ID: 23959314
[TBL] [Abstract][Full Text] [Related]
19. Antibiotic treatment of multidrug-resistant organisms in cystic fibrosis.
Conway SP; Brownlee KG; Denton M; Peckham DG
Am J Respir Med; 2003; 2(4):321-32. PubMed ID: 14719998
[TBL] [Abstract][Full Text] [Related]
20. [Susceptibilities of bacteria isolated from patients with respiratory infectious diseases to antibiotics (1994)].
Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Kobayashi K; Satou K; Matsumiya H; Saito A; Terai T; Tanno Y; Nishioka K; Arakawa M; Wada K; Okada M; Ozaki K; Aoki N; Kitamura N; Sekine O; Suzuki Y; Matsuda M; Tanimoto H; Nakata K; Nakamori Y; Kusano N
Jpn J Antibiot; 1996 May; 49(5):419-55. PubMed ID: 8752860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
